Skip to main content

Table 2 Toxicities in Level 0 cohort

From: Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014

Toxicity

G1, %

G2, %

G3, %

G4, %

Hematologic

    

 Neutropenia

0

0

11

89

 Leukopenia

0

11

56

33

 Anemia

56

22

0

0

 Thrombocytopenia

56

11

0

0

Nonhematologic

    

 AST increased

33

0

11

0

 ALT increased

33

0

11

0

 Anorexia

11

33

22

0

 Stomatitis

11

22

11

0

 Nausea

11

33

0

0

 Diarrhea

22

22

0

0

 Vomiting

22

11

0

0

 Allergic reaction

22

11

0

0

 Hypertension

0

11

0

0

 Dyspnea

0

11

0

0

 Peripheral neuropathy

44

0

0

0

 Constipation

33

0

0

0

 Edema limbs

22

0

0

0

 Weight loss

11

0

0

0

 Febrile neutropenia

-

-

11

0

 Infection

0

0

11

0

 Sepsis

-

-

-

22

 Hypoxia

-

0

11

0

  1. ALT: Alanine aminotransferase, AST: aspartate aminotransferase, G: Grade (according to the National Cancer Institute’s Common Toxicity Criteria for Adverse Events, version 4.0)